accounts for approximately 20% of all adult HIV-associated pneumonias, compared with 10% to 15% in the general population [6] . Most information on this population is based on case reports published between 1994 and 2001 [7] [8] [9] . However, in some studies performed between 1983 and 2001 [6, 9, 10] , L. pneumophila pneumonia has been observed to occur up to 40 times more frequently in patients in whom AIDS develops than in the general population [11] . Furthermore, some of these studies suggest that pneumonia caused by L. pneumophila tends to present with more severe clinical features in HIVinfected patients and requires special attention [6, 9, 10] . Given the conflicting information on clinical outcomes of Legionella pneumonia in HIV-infected patients, the aim of this study was to investigate whether the clinical presentations and outcomes (length of hospital stay [LOS] , intensive care unit [ICU] admission, and 30-day mortality rates) of Legionella pneumonia in HIV-infected patients were comparable to those seen in non-HIV-infected patients, using a case-control design.
METHODS
We performed a multicenter observational case-control study in 3 Spanish hospitals, 2 in Barcelona and 1 in Badalona. Case patients were defined as HIV-infected adults (aged ≥18 years) with a diagnosis of community-acquired Legionella pneumonia between 1994 and 2016. Three control patients who had Legionella pneumonia without HIV infection were selected for each case patient. Matched criteria included similar age (±10 years) and same center, sex, baseline pneumonia severity index (PSI) score of I-III or IV-V, and pneumonia diagnosis in the same calendar period (±1 year). Study outcomes included ICU admission, LOS, and 30-day mortality rate.
The study was approved by the ethics committee of our institution (No. 2009/5451). The need for written informed consent was waived due to the noninterventional design.
RESULTS
CAP caused by L. pneumophila was diagnosed in 32 consecutive case patients (HIV infected) and 96 controls (non-HIV infected) (Figure 1 ). It thus accounted for 128 (4%) of all episodes of CAP diagnosed in the 3 hospitals and 32 (6%) of the 565 HIV-infected patients with CAP. Of the 32 case patients included, 25 (78%) were male, with a median age of 40.0 years (interquartile range [IQR] , 38-50 years). Data on the probable route of exposure were available in 53% of case patients. HIV infection was acquired through homosexual, injection drug use, and heterosexual transmission in 4 (24%), 6 (35%), and 7 (41%) of the case patients, respectively. Twenty-three case patients (74%) were receiving ART at the time of diagnosis. ART regimens were based on nonnucleoside reverse-transcriptase inhibitors, protease inhibitors, integrase inhibitors, and other regimens in 3 (19%), 3 (19%), 9 (56%), and 8 (34%) of the case patients, respectively. Thirteen of these 23 patients (54%) had an undetectable HIV RNA viral load in plasma (<200 copies/mL). The median CD4 + T-cell count before diagnosis was 335/µL (IQR, 215-500/µL), 2 case patients (22%) received prophylaxis against Pneumocystis jirovecii pneumonia, and an AIDS-defining disease was diagnosed in 1 (3%). Most patients (84%) were classified as low risk (PSI risk class I-III). Ten patients (31%) presented with hepatitis C virus coinfection, and 1 (3%) with hepatitis B virus coinfection. Three patients (9%) were admitted to the ICU, and 2 of them (6%) required mechanical ventilation. The median LOS was 7.0 days (IQR, 4.0-11.0 days). The overall 30-day mortality rate was 3%. Baseline characteristics in case patients and controls are given in Table 1 and did not differ significantly between groups. Case patients were younger than controls and had a higher rate of hepatitis C virus coinfection and neurological disease. Diagnosis was by means of urinary antigen test in 124 patients (98%) and sputum culture in 8 (16%).
The most frequent empirical antibiotic treatment were ß-lactam plus macrolide (13 case In a multivariate logistic regression analysis, previous antibiotic treatment, PSI risk class IV-V, ratio of the partial pressure of oxygen in arterial blood to the fraction of inspired oxygen <250, the presence of pleural effusion, and the presence of multilobar involvement were associated with ICU admission (area under the receiver operating characteristic curve for the predictive model, 0.89; 95% confidence interval, .81-.97]). In a multivariate analysis, multilobar involvement and a white blood cell count <10 × 10 9 /L were associated with prolonged LOS (>6 days; cutoff, median LOS) (area under the receiver operating characteristic curve for the predictive model, 0.68; 95% confidence interval, .57-.80). HIV infection was not associated with ICU admission or increased LOS in the univariate analyses, even after adjustments for case patient and potential confounding factors in the multivariate analyses. In a univariate analysis of HIV-infected patients, we did not observe a relationship between ICU admission or LOS and receipt of ART, a plasma HIV RNA viral load <200 copies/mL, or a CD4 + cell count <200/μL (data not shown).
DISCUSSION
To the best of our knowledge, this is the first case-control study performed in HIV-infected patients with community-acquired Legionella pneumonia, and our main conclusion is that HIVinfected individuals presented neither a more severe disease nor a worse clinical outcome than matched HIV-negative control patients. An interesting observation in our study is that we did not find differences in antimicrobial treatment between case patients and controls. The similarities that we observed between HIV-infected and uninfected patients regarding clinical outcomes of Legionella pneumonia indicate that Legionella infection affected patients with correct immunological status more frequently. Information on Legionella infection and prognosis in HIVinfected patients is controversial. Some studies before the advent of ART reported a worse prognosis in HIV patients with Legionella pneumonia, with more complications; however, other studies, especially in the post-ART era, showed few significant differences. In our study, HIV infection was well controlled in most case patients. However in a study of Legionella disease in HIV-infected patients carried out in the pre-ART era , the immunological characteristics were similar to those recorded in our population [1] . In all likelihood, Legionella infections do not develop in HIV-infected patients with poor immune status owing to the cotrimoxazole prophylaxis they receive.
The main limitation of our study was that it was conducted over a long period of time. However, protocols and microbiological procedures have not substantially changed in this period. A second limitation is that although we found no differences in outcomes between case and control patients, we were able to analyze only 32 case patients, and this sample size may have led to a large type II error. Nonetheless, our sample size was larger than that in many previously reported studies of Legionella pneumonia in HIV-infected patients.
As a third limitation, we did not have data about the duration from onset of symptoms to Legionella pneumonia diagnosis and the start of target antibiotic therapy. However, all case patients in our study received adequate empiric antibiotic therapy. Fourth, though we included consecutive case patients, 54% had virological suppression, and because of the small number of case patients included our results cannot be extrapolated to nonsuppressed HIV-infected patients. Fifth, although L. pneumophila serotype 1 has been associated with 90% of cases reported in Europe, and also in Catalonia (the region where our study was performed), it is possible to misdiagnosis other species or serotypes of Legionella, because the urinary antigen test is insensitive for the detection of non-Pontiac monoclonal subtypes of L. pneumophila serogroup 1 and extremely insensitive for the detection of other L. pneumophila serogroups and Legionella species. In conclusion, this case-control study describes a subpopulation of HIV-infected patients with Legionella pneumonia in whom clinical presentation and outcomes did not differ from those in patients with similar clinical characteristics but without HIV infection. The management of these HIV-infected patients should be the same as for HIV-uninfected individuals and should be included in CAP management guidelines.
Notes

